Therapeutic uses of chemokine variants
US7740833B2 · kind B2 · utility
4Cited by
5References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2004 |
| Grant date | Jun 22, 2010 |
| Priority date | — |
| Expiry date | Nov 27, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/285
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.